A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study

L. G. Feun, J. A. Blessing, R. J. Barrett, P. Hanjani

Research output: Contribution to journalArticle

67 Scopus citations

Abstract

A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.

Original languageEnglish (US)
Pages (from-to)506-508
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number6
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.

  • Cite this